Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Kairos Therapeutics Canada

Kairos Therapeutics has developed a proprietary next generation antibody-drug conjugate (ADC) platform based on novel toxin, linker and site-specific conjugation technology. Kairos has demonstrated superior pre-clinical in-vivo efficacy over T-DM1. Further pre-clinical studies demonstrate Kairos’ ADCs have superior tolerability and therapeutic index, compared to other leading platforms which may lead to greater clinical efficacy. Through key partnerships, Kairos is developing a novel therapeutic pipeline and is out-licensing its ADC platform to companies seeking access to state-of-the-art technology.  

Website:
http://kairostherapeutics.com/
Year Founded
2014
Main Sector
Biotech Subsector
John Babcook
President & CSO 

Kalgene Pharmaceuticals

Website:
http://www.kalgene.com
Nathan Yoganathan
CEO 

Kineta United States

Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

Website:
www.kinetabio.com
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview

Kineta® is developing a pipeline of next-generation medicines to respond to the needs of millions of people facing diseases around the world. Our scientific areas of expertise are immunology and neuropathic pain with research directed at curbing inflammation and returning the immune system to normal function. Kineta has five unique drug programs in development and each program represents a novel mechanism-of-action and has potential to result in a new class of drug. The innovative portfolio is derived from leading edge scientific research that taps into promising recently discovered cellular channels that control the body's defense mechanisms. Kineta’s drug programs are designed to enhance or modulate the natural human immune system and show great potential to be more effective, more tolerable and confer fewer side effects than existing drugs. We anticipate our products will be highly sought after by patients, healthcare providers and the pharmaceutical industry.

Alliance & Collaborations
27 Scientific and academic collaborations
Current Financing Needs

Series B round of $5M with follow on series C for an additional $20M.

Current Timeline

Autoimmune drug successfully completed phase I clinical trials and is currently in a phase 1B extension study to be completed 1st quarter.  In discussions with numerous large pharmaceutical and biotechnology companies around a licensing transaction.

Antiviral and pain programs are currently in pre-clinical development with high industry interest.  We are in significant partnering discussions around several of our anti-viral drug candidates.

Current Investors

We have raised $36M since 2008.  This has been augmented with an additional $52M in NIH funding.

Our current investors are accredited investors, high net worth individuals, Family Offices, a boutique PE group and the Iacocca Foundation.

IP Status
  Protected Pipeline Secured with a
Valuable IP Portfolio ØStrong IP across each development program ØProprietary expertise in innate immunity & autoimmunity Ø27 Patent Families (28 owned, 6 in-licensed) •45 Issued Patents •154 Pending country applications •7 Pre-nationalized PCT or provisional families
Management Team Highlights

Chuck Magness, PhD

CEO

Human Genome Project; Co-founded & Sold Illumigen Biosciences ($17M + 321M); Kineta Enterprise >$60M

Shawn Iadonato, PhD

CSO

Human Genome Project; Illumigen Biosciences; Grew 5 Kineta Programs; 1st Kv1.3 in Clinic; >$35M  R&D Funds

Craig Philips, MBA

Commercial Operations

 VP & GM, Schering Plough, VP & GM, Bayer, President & GM CTI

Blake Ilstrup, JD

General Counsel /

Corporate Dev.

Hundreds of transactions with Cooley and Venture Law Group, General Counsel of Qpass, 6 Kineta transactions

Rob Hedequist

Corporate Development

Major Accounts, Managed Care & Sales/ Marketing Pfizer and Amgen; National Director Schering–Plough

Dan Eramian

Corporate Communications

First VP of communications for Biotech Industry Organization; US DOJ Director of Public Affairs; SBA

Ken North

Corporate Development

Founding CEO Seattle Savings Bank; Past president Seattle Kiwanis, Chamber of Commerce; Seafair Commodores

Dan Burge, MD

Clinical

Trubion (CMO), VP Early Development Immunex, Amgen (early development on Enbrel)

Jeff Fellows

Regulatory

Global Regulatory Lead Amgen,  VP Regulatory Alder, VP Regulatory CTI,  First Kv1.3 in clinic, Sensipar Amgen
Mr Rob Hedequist
Senior Vice President Corporate Development 
Blake Ilstrup
Jacques Bouchy